A Phase 2 interventional study of SAR445399 and Placebo in Non-cystic Fibrosis Bronchiectasis, sponsored by Sanofi. Suspended at 4 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Bronchiectasis with a site in United States — 21 open to participants now, 23 under way, 2 of them phase 3. Bronchiectasis · United States.
Among the 65 studies in Bronchiectasis with a site in United States, this one is the 27th largest by planned enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2026, is one of 15 in phase 2, and was the 61st registered.
404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.
Browse Bronchiectasis studies →21 of the 65 studies in Bronchiectasis with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States
Ages 18–80
Indiana University · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 22 more countries
Ages 12+
GlaxoSmithKline · Sites in United States, Argentina, China and 9 more countries
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 12 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
First in 1988; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is above the median of 60 across 263 interventional studies indexed under Bronchiectasis.
Median enrollment 78 across the 52 interventional studies, 100 across the 13 observational. Of the 39 that completed or were terminated, 20 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 65 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 2 studies filed under Bronchiectasis — fewer than ten, so there is no comparison to draw.
8 of the studies in Bronchiectasis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06872892Phase 3Boehringer IngelheimThe AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis | 2027-06-15 |
| NCT05860803Mayo ClinicBreathing Training and Exercise Capacity in Non-CFB | 2026-12-01 |
| NCT07135284Synchrony-Medical, LtdReal Life Evaluation of the LibAirty Airway Clearance System in Adults With Bronchiectasis (RELACS) | 2027-02 |
| NCT05846230Boehringer IngelheimClairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine | 2027-03-31 |
| NCT03839992Gelb, Arthur F., M.D.Detection of Unsuspected Small Airways Obstruction in Cystic Fibrosis | 2027-04-25 |
Add all 8 to your calendar (.ics) → With an account.
Among the 65 studies in Bronchiectasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score at 24 weeks of treatment with SAR445399 compared with placebo in adult participants aged 18 to 80 years with non-cystic fibrosis bronchiectasis (NCFB).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive SAR445399
Biological: SAR445399
Participants will receive placebo
Biological: Placebo
Pharmaceutical form: solution for injection Route of administration: injection
Pharmaceutical form: solution for injection Route of administration: injection
Change from baseline to Week 24 in mucus plug score (MPS) derived from chest high-resolution computerized tomography (HRCT)
Mucus plug score is determined by counting the number of bronchopulmonary segments that contain at least one mucus plug, defined as a complete occlusion of the airway The total MPS ranges from 0 to 18 with higher scores indicating worse outcome
Time frame: from baseline up to Week 24
Change from baseline to Week 24 in post-bronchodilator forced expiratory volume in 1 second (FEV1)
Post-bronchodilator forced expiratory volume in 1 second
Time frame: from baseline up to Week 24
Change from baseline to Week 52 in post-bronchodilator forced expiratory volume in 1 second (FEV1)
Post-bronchodilator forced expiratory volume in 1 second
Time frame: from baseline up to Week 52
Change from baseline to Week 24 in pre-bronchodilator forced expiratory volume in 1 second (FEV1)
Pre-bronchodilator forced expiratory volume in 1 second
Time frame: from baseline up to Week 24
Change from baseline to Week 52 in pre-bronchodilator forced expiratory volume in 1 second (FEV1)
Pre-bronchodilator forced expiratory volume in 1 second
Time frame: from baseline up to Week 52
Annualized rate of pulmonary exacerbation (PEx) from baseline up to Week 24
Pulmonary exacerbations (PEx) were defined as a worsening of 3 or more major symptoms over a 48-hour period, including increased cough, increased sputum volume or changes in sputum consistency, increased sputum purulence, increased breathlessness, decreased exercise tolerance, fatigue and/or malaise, and hemoptysis. These symptoms had to lead to a healthcare provider's decision to prescribe systemic antibiotics
Time frame: from baseline up to Week 24
Annualized rate of pulmonary exacerbation (PEx) from baseline up to Week 52
Pulmonary exacerbations (PEx) were defined as a worsening of 3 or more major symptoms over a 48-hour period, including increased cough, increased sputum volume or changes in sputum consistency, increased sputum purulence, increased breathlessness, decreased exercise tolerance, fatigue and/or malaise, and hemoptysis. These symptoms had to lead to a healthcare provider's decision to prescribe systemic antibiotics
Time frame: from baseline up to Week 52
Responder status for being exacerbation-free over the 24-week study period
Proportion of patients without a pulmonary exacerbation (PEx) event from baseline up to Week 24
Time frame: from baseline up to Week 24
Responder status for being exacerbation-free over the 52-week study period
Proportion of patients without pulmonary exacerbation (PEx) event from baseline up to Week 52
Time frame: from baseline up to Week 52
Annualized rate of severe pulmonary exacerbation (PEx) from baseline up to Week 24
A pulmonary exacerbation is classified as severe when it necessitates either:Intravenous antibacterial treatment, and/or hospital admission
Time frame: from baseline up to Week 24
Annualized rate of severe pulmonary exacerbation (PEx) from baseline up to Week 52
A pulmonary exacerbation is classified as severe when it necessitates either:Intravenous antibacterial treatment, and/or hospital admission
Time frame: from baseline up to Week 52
Responder status for being severe exacerbation-free over the 24-week study period
Proportion of patients without a severe pulmonary exacerbation (PEx) event from baseline up to Week 24
Time frame: from baseline up to Week 24
Responder status for being severe exacerbation-free over the 52-week study period
Proportion of patients without a severe pulmonary exacerbation (PEx) event from baseline up to Week 52
Time frame: from baseline up to Week 52
Incidence of treatment-emergent adverse events (TEAEs), adverse event of special interests (AESIs), serious adverse events (SAEs), adverse events (AEs) leading to permanent study treatment discontinuation throughout the study
Incidence of participants with TEAEs, including AESIs, and SAEs
Time frame: from baseline up to Week 66
Incidence of potentially clinically significant abnormalities in laboratory tests, vital signs, and 12-lead electrocardiograms (ECGs) throughout the study
Time frame: from baseline up to Week 66
Plasma concentration of SAR445399 at prespecified timepoints throughout the study
Time frame: from baseline up to Week 66
Incidence of anti-drug antibodies (ADAs) against SAR445399 throughout the study
Time frame: from baseline up to Week 66
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Started Jun 2026 (actual). Primary completion is estimated for Oct 2027, 16 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is suspended, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.